Given that the spliceosome SF3b complex has emerged as a potential therapeutic target [31], we sought to define whether cancer models harbouring SF3B1 hotspot mutations would be sensitive to chemical inhibition of SF3B1and RNA-interference silencing of SF3B1 and genes abnormally spliced in SF3B1 mutant tumours [32]. The gene discussed is SF3B1; the disease is cancer.